Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.57
-0.23 (-2.35%)
At close: Feb 21, 2025, 4:00 PM
9.70
+0.13 (1.36%)
After-hours: Feb 21, 2025, 4:11 PM EST
Vir Biotechnology Employees
Vir Biotechnology had 587 employees as of December 31, 2023. The number of employees increased by 11 or 1.91% compared to the previous year.
Employees
587
Change (1Y)
11
Growth (1Y)
1.91%
Revenue / Employee
$133,932
Profits / Employee
-$908,593
Market Cap
1.32B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Dec 31, 2020 | 327 | 98 | 42.79% |
| Dec 31, 2019 | 229 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
VIR News
- 2 days ago - Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference - Business Wire
- 9 days ago - Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
- 5 weeks ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 6 weeks ago - Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why - Benzinga
- 6 weeks ago - Vir Biotechnology: A Rocket Off Phase 1 Data - Seeking Alpha
- 6 weeks ago - Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why - Benzinga
- 6 weeks ago - Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC - Business Wire
- 2 months ago - Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire